Tag Drug Discovery

A good month for public access to research

July has been a great month. Three new publications with Lipotype Shotgun Lipidomics technology have been put out, and the Lipidomics Resource Center received its first major update. Read more about this!


One month – three publications

This month, three new publications with Lipotype Shotgun Lipidomics technology were published!

Paper 1: Parkinson’s disease
In Parkinson’s, excessive contacts between mitochondria and endoplasmic reticulum lead to abnormal lipid trafficking. This stops the release of “sleep” peptides affecting sleep patterns of patients long before they experience motor dysfunctions

Paper 2: vacciness
Adjuvants like the well-established AS03 are agents in vaccines that do not provide immunity but stimulate the immune system. However, the molecular mechanism behind AS03’s adjuvant effect had yet to be fully illuminated. These new results could be applied to design novel vaccine adjuvants

Paper 3: cancer therapeutics
Oncogenic RAS proteins must localize to the plasma membrane to act. The recently described oxanthroquinone G01 disrupts that, affects levels of some lipids and synergizes with other compounds that affect oncogenic RAS proteins. G01 could become a new anti-RAS therapeutic

As always: access the Lipidomics Resource Center to study more publications!


The first major Lipidomics Resource Center update

We strive for scientific excellence, and therefore must hold on to the fact that all science is just as good as the research which precedes it. Therefore, we created the Lipidomics Resource Center which provides access to lipidomics publications and whitepapers to empower your research. However, that is just not enough. Therefore we added a completely new category: “products”!

There is a whole universe of research which you cannot access through reading scientific publications. And that is most of industry research. However, this type of research is reflected by product development and patents. The new category “products” gives you access to exactly this kind of hidden information.

Lipidomics is no longer a thing of the lab. It is out in the world. Now, you can learn about it!


Follow us on LinkedIn, Twitter, Facebook or Google+, and subscribe to our newsletter to stay updated on lipids and lipidomics!

Lipotype’s customer Lyomark Pharma announces partnership

Lyomark Pharma, a customer of Lipotype, announces a partnership with Aerogen Pharma to develop an inhaled surfactant for the treatment of preterm infants with Respiratory Distress Syndrome (RDS). At the same time clinical trials with the new delivery system have been initiated and the first patients have been recruited. Read more in the press release of Lyomark and Aerogen:


Read more in the press release of Lyomark and Aerogen here:
Aerogen Pharma and Lyomark Pharma partner to develop inhaled surfactant, begin a Phase 2 clinical trial

Lipid analysis for early stages of drug discovery: Customer Reference Flagship VentureLabs

Lipotype performed lipid analysis for Flagship VentureLabs with the aim to better understand molecular compositions of chondrisomes, pharmaceutically active derivatives of mitochondria. The research of Flagship VentureLabs is on novel ways of preparation of chondrisomes that have beneficial structural characteristics, yield, concentration, stability, viability, integrity, or function. The lipidomic results facilitated the characterization of isolated chondrisomes in order to evaluate their quality and subsequently were used to file a recently published patent application.

Read more  


Read the patent application here
Methods and Compositions of Chondrisomes – United States Patent Application 20170151287, 2017
G A Von Maltzahn, J M Milwid, M Mee, J R Rubens, D Chess, K Trudeau, K Mahdaviani, J Feala

Release of White Paper: Big data lipidomics for lipid biomarker identification

Lipidomics is the large-scale investigation of lipids in biological systems. Venturing into the analysis of large dataset, with potential thousands of lipidomes, by advanced multiparametric statistical approaches is a challenging endeavour. We established algorithms and a full set of methods tailored to quantitative lipid data. This allows to perform statistical analysis and enrichment analysis in order to identify lipid biomarkers. In our recently published white paper a cohort of healthy subjects is compared with a cohort of diseased subjects. The result is a lipid signature that discriminates healthy from disease. Those could then potentially be of use for disease stratification or diagnosis by means of predictive modelling (machine learning). In this white paper, we will guide you through the data analysis process for lipid biomarkers.   Read more


Learn more about Big Data Lipidomics and get the White Paper.


Follow us on  LinkedIn Twitter or  subscribe to our newsletter